학술논문
P072 Activity and clinical outcomes of New Agents (NAs) administered as third or fourth line after the failure of docetaxel (DOC) and another NA in metastatic Castration-Resistant Prostate Cancer (mCRPC) patients. Final results of an Italian multicentre retrospective study
Document Type
Abstract
Author
Source
In European Urology Supplements November 2014 13(5):135-136
Subject
Language
ISSN
1569-9056